X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs PLETHICO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES PLETHICO PHARMA JUBILANT LIFE SCIENCES/
PLETHICO PHARMA
 
P/E (TTM) x 12.2 -1.1 - View Chart
P/BV x 1.7 0.0 10,268.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 JUBILANT LIFE SCIENCES   PLETHICO PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-18
PLETHICO PHARMA
Mar-14
JUBILANT LIFE SCIENCES/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,039395 263.1%   
Low Rs60031 1,916.9%   
Sales per share (Unadj.) Rs482.6604.4 79.8%  
Earnings per share (Unadj.) Rs40.732.5 125.4%  
Cash flow per share (Unadj.) Rs67.451.3 131.2%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs262.3473.6 55.4%  
Shares outstanding (eoy) m155.7934.08 457.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.70.4 481.7%   
Avg P/E ratio x20.16.6 306.7%  
P/CF ratio (eoy) x12.24.2 293.0%  
Price / Book Value ratio x3.10.5 694.3%  
Dividend payout %7.40-   
Avg Mkt Cap Rs m127,6707,262 1,757.9%   
No. of employees `0002.4NA-   
Total wages/salary Rs m15,5591,596 974.9%   
Avg. sales/employee Rs Th30,861.4NM-  
Avg. wages/employee Rs Th6,387.0NM-  
Avg. net profit/employee Rs Th2,604.4NM-  
INCOME DATA
Net Sales Rs m75,17820,598 365.0%  
Other income Rs m400386 103.6%   
Total revenues Rs m75,57920,984 360.2%   
Gross profit Rs m15,1842,818 538.9%  
Depreciation Rs m4,151642 646.2%   
Interest Rs m2,8431,593 178.4%   
Profit before tax Rs m8,591969 887.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,247-138 -1,623.5%   
Profit after tax Rs m6,3441,107 573.2%  
Gross profit margin %20.213.7 147.6%  
Effective tax rate %26.2-14.3 -183.0%   
Net profit margin %8.45.4 157.0%  
BALANCE SHEET DATA
Current assets Rs m31,89818,877 169.0%   
Current liabilities Rs m20,04711,896 168.5%   
Net working cap to sales %15.833.9 46.5%  
Current ratio x1.61.6 100.3%  
Inventory Days Days6836 188.0%  
Debtors Days Days55198 27.8%  
Net fixed assets Rs m60,7159,861 615.7%   
Share capital Rs m156341 45.7%   
"Free" reserves Rs m40,71012,331 330.2%   
Net worth Rs m40,86516,139 253.2%   
Long term debt Rs m30,4784,706 647.7%   
Total assets Rs m96,17633,146 290.2%  
Interest coverage x4.01.6 250.1%   
Debt to equity ratio x0.70.3 255.8%  
Sales to assets ratio x0.80.6 125.8%   
Return on assets %9.68.1 117.3%  
Return on equity %15.56.9 226.4%  
Return on capital %16.012.3 130.4%  
Exports to sales %021.4 0.0%   
Imports to sales %015.2 0.0%   
Exports (fob) Rs mNA4,402 0.0%   
Imports (cif) Rs mNA3,136 0.0%   
Fx inflow Rs m14,4024,402 327.1%   
Fx outflow Rs m12,0443,184 378.3%   
Net fx Rs m2,3581,219 193.5%   
CASH FLOW
From Operations Rs m13,0322,437 534.7%  
From Investments Rs m-6,177-6,265 98.6%  
From Financial Activity Rs m-9,0112,490 -361.9%  
Net Cashflow Rs m-2,123-1,337 158.7%  

Share Holding

Indian Promoters % 45.6 82.7 55.1%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 4.3 202.3%  
FIIs % 21.2 5.5 385.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 7.5 281.3%  
Shareholders   23,815 10,665 223.3%  
Pledged promoter(s) holding % 15.9 85.7 18.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   CIPLA  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  PIRAMAL ENTERPRISES  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex below 38,000-Mark, HUL, L&T Q1FY20 Results, and Top Stocks in Action Today(Pre-Open)

On Tuesday, Indian share markets extended their decline for the 4th day as markets witnessed selling pressure during closing hours.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY19); Net Profit Up 25.7% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 25.7% YoY). Sales on the other hand came in at Rs 24 bn (up 15.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY19); Net Profit Up 67.2% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 67.2% YoY). Sales on the other hand came in at Rs 23 bn (up 38.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Driverless Cars are Here. And This Tiny Company is in the Lead...(The 5 Minute Wrapup)

Jul 17, 2019

This future-ready company thrives on the pace of technological change.

Here's Why This Smallcap Will Beat the Big Autos in the EV Race(Profit Hunter)

Jul 16, 2019

As the conventional auto sector faces existential crisis, my latest smallcap recommendation is all set to ride the electric vehicle disruption and rise in new age vehicles.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Jul 23, 2019 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 5-YR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS